Valuation: Haleon plc

Capitalization 31.43B 42.51B 36.1B 33.33B 58.3B 3,956B 59.31B 391B 153B 1,903B 159B 156B 6,767B P/E ratio 2026 *
18.3x
P/E ratio 2027 * 16.6x
Enterprise value 38.28B 51.79B 43.98B 40.61B 71.01B 4,819B 72.25B 476B 187B 2,318B 194B 190B 8,243B EV / Sales 2026 *
3.36x
EV / Sales 2027 * 3.17x
Free-Float
89.25%
Yield 2026 *
2.24%
Yield 2027 * 2.49%
1 day+1.69%
1 week-1.59%
Current month-4.15%
1 month-9.29%
3 months-0.78%
6 months+1.85%
Current year-4.40%
1 week 351.1
Extreme 351.1
363.7
1 month 351.1
Extreme 351.1
394.6
Current year 351.1
Extreme 351.1
416.1
1 year 274.4
Extreme 274.4
419.5
3 years 274.4
Extreme 274.4
419.5
5 years 241.17
Extreme 241.1735
419.5
10 years 241.17
Extreme 241.1735
419.5
Manager TitleAgeSince
Chief Executive Officer 59 22/07/2021
Director of Finance/CFO 56 01/11/2024
Chief Tech/Sci/R&D Officer 63 01/08/2025
Director TitleAgeSince
Director/Board Member 59 23/05/2022
Chairman 71 01/01/2026
Director/Board Member 59 18/07/2022
Change 5d. change 1-year change 3-years change Capi.($)
+1.66%-1.59%-5.83%+3.99% 42.51B
+2.72%-1.22%+10.48%+149.23% 809B
+0.27%-1.73%+48.82%+41.45% 565B
+1.24%+1.77%+22.33%+31.29% 370B
+0.81%-0.35%+24.06%+13.94% 320B
+1.32%-1.43%+48.28%+26.96% 312B
+1.58%-3.62%+50.03%+1.75% 285B
+0.45%-3.25%+29.98%+33.71% 286B
+1.31%+0.62%+27.38%+42.38% 189B
+1.24%+7.92%-33.41%-55.35% 180B
Average +1.27%-1.80%+22.21%+28.93% 335.69B
Weighted average by Cap. +1.37%-2.45%+26.45%+52.70%

Financials

2026 *2027 *
Net sales 11.41B 15.43B 13.11B 12.1B 21.16B 1,436B 21.53B 142B 55.59B 691B 57.9B 56.69B 2,457B 11.91B 16.12B 13.69B 12.64B 22.1B 1,500B 22.48B 148B 58.05B 721B 60.46B 59.2B 2,565B
Net income 1.74B 2.35B 2B 1.84B 3.22B 219B 3.28B 21.61B 8.47B 105B 8.82B 8.64B 374B 1.9B 2.57B 2.18B 2.01B 3.52B 239B 3.58B 23.6B 9.25B 115B 9.63B 9.43B 409B
Net Debt 6.85B 9.27B 7.88B 7.27B 12.72B 863B 12.94B 85.22B 33.4B 415B 34.79B 34.06B 1,476B 6.3B 8.52B 7.24B 6.68B 11.69B 793B 11.89B 78.32B 30.7B 382B 31.97B 31.3B 1,357B
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (29.5%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (22.8%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (17.7%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - vitamins, minerals and food supplements (15.1%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. - respiratory medicines (14.9%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.2%), North America (36%), and Asia/Pacific (22.8%).
Employees
24,535
Date Price Change Volume
17/04/26 358.10 p +1.59% 7,063,352
16/04/26 352.50 p -0.17% 11,434,920
15/04/26 353.10 p -1.15% 23,282,860
14/04/26 357.20 p -0.92% 20,375,230
13/04/26 360.50 p -0.99% 39,782,560
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.525GBP
Average target price
4.254GBP
Spread / Average Target
+20.68%

Quarterly revenue - Rate of surprise